Plain-English translation of NCT06517017 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a gentler way to treat very frail patients with multiple myeloma using a combination of medications including , dexamethasone, and lenalidomide. Rather than starting all medications at once, doctors will introduce the treatment slowly — beginning with two medications and adding the third medication later — to give your body time to adjust. The goal is to help patients stay on treatment longer and feel better overall.
Patients with multiple myeloma who are very frail often struggle to stay on standard treatments and face serious health risks early on. This trial is testing whether a slower, gentler approach to starting this medication might help these vulnerable patients tolerate treatment better and maintain a better quality of life.
You likely qualify if…
You likely don't qualify if…
You will receive the medication through intravenous infusion and pills by mouth according to a slow, gentle schedule designed specifically for frail patients. The trial will begin with just two of the three medications, and a third medication will be added starting in the third cycle of treatment to give your body time to adjust. You will have regular visits with your doctor to monitor how you're doing, check your side effects, and assess your quality of life throughout the study.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States